Pfizer Takes ‘Opportunistic’ Approach To Future Biosimilars
Company Sees 93% Growth In Biosimilars Business To $559m In Q2
Pfizer reported double-digit growth in its biosimilars and sterile injectables segments, as the company indicated that it would take a more “opportunistic” approach to its biosimilars business in future. The company has also revised its overall 2021 financial guidance as it expects better numbers on the back of its COVID-19 vaccine business.
